18_CD
17c_JJ
GROUP_NN
PROFIT_NN
AND_PHC
LOSS_NN
ACCOUNT_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
Cost_NN
of_PIN
sales_NN
-_:
restatement_NOMZ
2001_CD
2000_CD
The_DT
Group_NN
has_VPRT [PEAS]
begun_VBN
to_TO
classify_VB
the_DT
2002_CD
restated_VBN
restated_VBN
Notes_NN
000 000 000_CD
costs_NN
directly_RB
attributable_JJ
to_PIN
funded_JJ
Turnover_NN
2_CD
79,716_CD
8,914_CD
6,264_CD
research_NN
and_PHC
vaccine_NN
manufacture_NN
Cost_NN
of_PIN
sales_NN
49,249_CD
5,063_CD
517_CD
programs_NN
as_IN
cost_NN
of_PIN
sales_NN
,_,
rather_CONJ
Gross_NN
profit_NN
30,467_CD
3,851_CD
5,747_CD
than_PIN
research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
costs_NN
16,299_CD
12,594_CD
12,195_CD
expenditure_NN
._.
This_DEMP
is_VPRT
because_CAUS
the_DT
Administrative_JJ
costs_NN
including_VBG [WZPRES]
amortisation_NOMZ
of_PIN
goodwill_NN
3_CD
4,257_CD
3,499_CD
2,949_CD
Directors_NN
believe_VPRT [PRIV]
this_DEMO
classification_NOMZ
Group_NN
operating_GER
profit_NN
loss_NN
4_CD
9,911_CD
12,242_CD
9,397_CD
more_EMPH
appropriately_RB
reflects_VPRT [PRIV]
the_DT
Share_NN
of_PIN
loss_NN
of_PIN
joint_JJ
venture_NN
14_CD
d_SYM
171_CD
410_CD
2,138_CD
nature_NN
of_PIN
the_DT
arrangements_NOMZ
into_PIN
Total_JJ
operating_GER
profit_NN
loss_NN
before_IN
exceptional_JJ
items_NN
Group_NN
and_CC
joint_JJ
venture_NN
9,740_CD
12,652_CD
11,535_CD
which_WDT
the_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
._.
In_PIN
the_DT
Exceptional_JJ
items_NN
:_:
three_CD
financial_JJ
years_NN
shown_VBN [PRIV]
,_,
cost_NN
of_PIN
Profit_NN
on_PIN
disposal_NN
of_PIN
fixed_JJ
asset_NN
investment_NOMZ
-_:
-_:
221_CD
sales_NN
represent_VPRT
only_DWNT
those_DEMO
costs_NN
Profit_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
-_:
-_:
414_CD
incurred_VBN
on_PIN
the_DT
two_CD
CDC_NN
smallpox_NN
Amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
fixed_VBN
asset_NN
investment_NOMZ
5_CD
85 423 670_CD
vaccine_NN
contracts_NN
._.
The_DT
restatement_NOMZ
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
finance_NN
charges_NN
9,655_CD
13,075_CD
11,570_CD
of_PIN
2001_CD
and_CC
2000_CD
costs_NN
from_PIN
R&D_NN
Interest_NN
receivable_JJ
685 857 983_CD
costs_NN
to_PIN
cost_NN
of_PIN
sales_NN
amounted_VBD
to_PIN
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
6_CD
1,211_CD
214_CD
216_CD
5.1_CD
m_NN
and_CC
0.1_CD
m_NN
respectively_RB
._.
There_EX
Exchange_NN
gain_NN
loss_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
18 449 126 271_CD
is_VPRT [BEMA]
no_SYNE
impact_NN
on_PIN
net_JJ
profit_NN
._.
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
7_CD
9,578_CD
12,558_CD
11,074_CD
Taxation_NOMZ
10_CD
3_CD
131_CD
-_:
Turnover_NN
and_PHC
profit_NN
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
being_VBG [WZPRES] [PASS]
retained_VBN
profit_NN
loss_NN
for_PIN
the_DT
financial_JJ
year_NN
9,575_CD
12,427_CD
11,074_CD
The_DT
increase_NN
in_PIN
turnover_NN
and_CC
the_DT
Earnings_GER
loss_NN
per_PIN
ordinary_JJ
share_NN
basic_JJ
11_CD
10.0_CD
p_NN
13.7_CD
p_VPRT
13.9_CD
p_JJ
Earnings_GER
loss_NN
per_PIN
ordinary_JJ
share_NN
fully_AMP
diluted_VBN
11_CD
9.7_CD
p_NN
13.7_CD
p_VPRT
13.9_CD
p_JJ
recording_GER
of_PIN
a_DT
maiden_JJ
profit_NN
in_PIN
2002_CD
has_VPRT [SPAU] [PEAS]
principally_RB
been_VBN [BYPA]
driven_VBN
by_PIN
the_DT
A_NN
statement_NOMZ
of_PIN
movements_NOMZ
on_PIN
reserves_NN
is_VPRT [PASS]
given_VBN
in_PIN
note_NN
22_CD
._.
second_JJ
smallpox_NN
vaccine_NN
contract_NN
with_PIN
the_DT
US_FPP1
Government_NOMZ
agency_NN
,_,
the_DT
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
this_DEMO
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
._.
Centers_NN
for_PIN
Disease_NN
Control_NN
and_CC
All_QUAN
amounts_NN
in_PIN
2002_CD
arise_VB
from_PIN
continuing_VBG
operations_NOMZ
see_VPRT [PRIV]
note_NN
4_CD
._.
Taxation_NOMZ
The_NN
tax_NN
charge_NN
relating_VBG [WZPRES]
to_PIN
2002_CD
was_VBD [BEMA]
negligible_JJ
due_JJ
to_PIN
the_DT
availability_NOMZ
of_PIN
tax_NN
losses_NN
within_PIN
the_DT
Group_NN
._.
We_FPP1
hope_VPRT [PRIV]
that_THVC
when_RB
the_DT
remaining_VBG
tax_NN
17d_CD
GROUP_NN
STATEMENT_NOMZ
OF_PIN
TOTAL_NN
RECOGNISED_NN
GAINS_NN
AND_PHC
LOSSES_NN
losses_NN
can_POMD
be_VB [PASS]
utilised_VBN
,_,
this_DEMP
will_PRMD
have_VB
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
the_DT
effect_NN
of_PIN
lowering_VBG
the_DT
effective_JJ
tax_NN
rate_NN
._.
2002 2001 2000 000_CD
000_CD
000_CD
Profit_NN
loss_NN
for_PIN
the_DT
year_NN
9,575_CD
12,427_CD
11,074_CD
Gain_NN
loss_NN
on_PIN
foreign_JJ
currency_NN
translation_NOMZ
1,276_CD
314_CD
817_CD
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
year_NN
10,851_CD
12,741_CD
11,891_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
this_DEMO
Group_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
THE_DT
INFORMATION_NOMZ
CONTAINED_VBD
IN_PIN
THIS_DEMO
COLUMN_NN
HAS_VPRT
NOT_XX0
BEEN_JJ
AUDITED_NN
._.
